A Novel Oxidative Stress-Related lncRNA Signature That Predicts the Prognosis and Tumor Immune Microenvironment of Breast Cancer

Figure 12

Comparison of sensitivity to treating drugs across high- and low-risk groups. (a) CD80, TNFSF4, CD276, and NRP1 expressions between groups. (b) IC50 of AKT inhibitor VIII between groups. (c) IC50 of AZD6482 between groups. (d) IC50 of bicalutamide between groups. (e) IC50 of BMS.708163 in the two risk groups. (f) IC50 of imatinib in the two risk groups. (g) IC50 of lapatinib in the two risk groups. (h) IC50 of pazopanib between groups, (i) IC50 of thapsigargin in the two risk groups, and (j) IC50 of methotrexate between groups.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)